Plasma-Based Longitudinal Evaluation of ESR1 Epigenetic Status in Hormone Receptor-Positive HER2-Negative Metastatic Breast Cancer

Overview of attention for article published in Frontiers in oncology, September 2020

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
Good Attention Score compared to outputs of the same age (70th percentile)
High Attention Score compared to outputs of the same age and source (89th percentile)

Mentioned by

twitter: 9 X users

Citations

dimensions_citation: 18 Dimensions

Readers on

mendeley: 52 Mendeley

Summary X Dimensions citations

So far, Altmetric has seen 12 X posts from 9 X users, with an upper bound of 7,123 followers.

@benelli_matteo @LMalorni @Biomol_MDPI @OncologiaPrato Great manuscript, #ctDNA MSddPCR is particularly promising for early resistance assessment in metastatic #breastcancer #MBC treated with endocrine therapy https://t.co/FgjGneot7S

20 Dec 2020

Reply Repost Favourite

Plasma-Based Longitudinal Evaluation of ESR1 Epigenetic Status in Hormone Receptor-Positive HER2-Negative Metastatic Breast Cancer. https://t.co/Uk2x59ygrC

21 Oct 2020

Reply Repost Favourite

Plasma-Based Longitudinal Evaluation of ESR1 Epigenetic Status in Hormone Receptor-Positive HER2-Negative Metastatic Breast Cancer. https://t.co/7PoFcWI00G https://t.co/bcilUbtLky

21 Oct 2020

Reply Repost Favourite

RT @LGerratana: #ctDNA #epigenetic characterization of ESR1 can be used for the early assessment of endocrine therapy sensitivity in HR-Pos…

20 Sep 2020

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity, including 8 additional X posts.